Halozyme Therapeutics Inc (HALO) Growth Rates Comparisons to Biotechnology & Pharmaceuticals Industry, Sector, Market. Sales, Income, EPS
CSIMarket Company Name, Ticker, Competitors, else..
 
Halozyme Therapeutics Inc   (NASDAQ: HALO)
 

Halozyme Therapeutics Inc Growth Comparisons

Select each growth Category to receive further Information




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

HALO Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q3 MRQ) 39.15 % 5.15 % 10.18 % 10.9 %
Q / Q Revenue Growth (Q3 MRQ) 2.49 % -11.92 % -2.46 % 8.32 %
Y / Y Revenue Growth (for 12 months ending Q3 TTM) 45.03 % 5.66 % 7.98 % %
Sequential Revenue Growth (for 12 months ending Q3 TTM) 8.34 % 1.16 % 2.1 % 2.61 %
Revenue 5 Year Average Growth 39.16 % 8.24 % 8.67 % 13.63 %


HALO's Growth Comparisons in III. Quarter 2026




Strong but slowing Revenue rise by Halozyme Therapeutics Inc of 39.15% year on year , in the third quarter 2026 to 493 millions, was higher than the 5.15% growth in the Biotechnology & Pharmaceuticals industry, and 10.18% improvement in the Healthcare sector. Despite modest Sales rises in the Healthcare sector and in the Biotechnology & Pharmaceuticals industry, Halozyme Therapeutics Inc reported above average market Sales growth.

Comparing the company's Revenue to the second quarter results, sales were higher by 2.49% . On the yearly basis, average annual sales growth for Halozyme Therapeutics Inc is 39.16%, while S & P 500's including only Businesses with the third quarter 2026 earnings, average annual sales growth is 13.63% over the past five years.

HALO Growth Rates by Company's Segments

Segment Name
Y / Y
Sequential
Royalty
-
62.18 %
Product
52.31 %
52.81 %
Collaborative Agreements
-
29.72 %
Proprietary Products Sales
-
57.12 %
Bulk rHuPH20
-
53.02 %
Device Partnered Products
-
37.69 %
Upfront Fees
-
8.45 %
Device licensing and development revenue
42.72 %
0 %
Sales-based Milestone
-
-
Device Licensing and Development
-
57.55 %
Total
39.15 %
2.49 %


Growth Rates of HALO's Income in the third quarter 2026


HALO Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q3 MRQ) 35.36 % 440.4 % 11.09 % 97.6 %
Sequential Operating Income Change (Q3 MRQ) 2.54 % -48.71 % -12.21 % 48.13 %
Y / Y Operating Income Growth (Q3 TTM) -8.56 % 996.83 % 30.98 % 40.67 %
Sequential Operating Income Growth (Q3 TTM) 12.9 % 230.02 % 4.93 % 20.86 %
Operating Income 5 Year Avg. Change 26.59 % -18.52 % 10.27 % 18.8 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q3 MRQ) 40.99 % -78.38 % -38.86 % 90.69 %
Sequential Income from Cont. Ops. Change (Q3 MRQ) 7.45 % - -63.27 % 27.07 %
Y / Y Income from Cont. Ops. Change (Q3 TTM) -18.48 % -86.28 % 9.88 % 57.33 %
Sequential Income from Cont. Ops. Change (Q3 TTM) 17.37 % -58.33 % -4.67 % 18.65 %
Income from Cont. Ops. 5 Year Avg. Change 19.68 % -11.53 % 8.91 % -28.64 %

HALO Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q3 MRQ) 40.99 % -79.71 % -39.2 % 90.69 %
Q / Q Net Income Growth (Q3 MRQ) 7.45 % -87.33 % 11.78 % 27.07 %
Y / Y Net Income Change (Q3 TTM) -18.48 % 102.94 % 15.43 % 57.33 %
Sequential Net Income Change (Q3 TTM) 17.37 % -7.86 % -6.73 % 18.65 %
Net Income 5 Year Avg. Growth 19.68 % -8.71 % 9.09 % 23.95 %

HALO's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q3 MRQ) 45.64 % -81.2 % -38.86 % 90.69 %
Sequential EPS from Cont. Ops. Change (Q3 MRQ) 10.71 % - -63.27 % 27.07 %
Y / Y EPS from Cont. Ops. Change (Q3 TTM) -13.77 % - - -
Sequential EPS from Cont. Ops. Change (Q3 TTM) 19.21 % - - 4.88 %
EPS from Cont. Ops. 5 Year Avg. Growth 22.68 % 38.54 % 8.91 % -28.64 %



HALO EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q3 MRQ) 40.56 % -82.35 % -39.2 % -28.64 %
Q / Q EPS Net Growth (Q3 MRQ) 5.79 % -88.49 % 11.78 % 27.07 %
Y / Y EPS Net Change (for 12 months ending Q3 TTM) - - - 7.62 %
Sequential EPS Net Change (for 12 months ending Q3 TTM) 17.01 % - 10.63 % 4.93 %
EPS Net 5 Year Avg. Change 22.98 % -8.71 % 9.09 % 23.95 %



Halozyme Therapeutics Inc showed impressive 40.56% year on year rise in the third quarter to $2.01, despite the -82.35% inBiotechnology & Pharmaceuticals industry, Healthcare sector dropped -39.2%. Slow third quarter 2026 income per share, in Biotechnology & Pharmaceuticals industry and Healthcare sector, were portrayed in the Halozyme Therapeutics Inc results which underperformed overall market.

Comparing company's EPS to the second quarter results, income per share were higher by 5.79% . On the yearly basis, average annual income per share growth for Halozyme Therapeutics Inc is 22.98%, while S & P 500's including only the businesses with the third quarter 2026 Results, average annual income per share growth is 23.95% over the past five years.

HALO Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q3 MRQ) 45.37 % 6160.46 % 44.26 % 48.62 %
Sequential Free Cash Flow Change (Q3 MRQ) 7.82 % -53.34 % -42.65 % 34.18 %
Y / Y Free Cash Flow Change (Q3 TTM) 47.06 % 10.87 % 19.33 % 60.27 %
Sequential Free Cash Flow Change (Q3 TTM) 9.88 % 17.82 % 5.88 % 15.75 %
Free Cash Flow 5 Year Avg. Change 64.19 % -13.84 % 0.41 % 1.8 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q3 MRQ) - - - 339.02 %
Sequential Net Cash Flow Change (Q3 MRQ) - 33.74 % - 216.68 %
Y / Y Net Cash Flow Change (Q3 TTM) - 783.99 % - 209.43 %
Sequential Net Cash Flow Change (Q3 TTM) - - - 152.64 %
Net Cash Flow 5 Year Avg. Change -5.66 % 23.25 % 6.46 % 1.07 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q3 MRQ) 0.66 % 31.06 % 10.33 % 120.03 %
Sequential Capital Expenditures Change (Q3 MRQ) -26.91 % -4.21 % -19.32 % 36.87 %
Y / Y Capital Expenditures Change (Q3 TTM) 44.17 % 9.75 % 9.34 % 109.38 %
Sequential Capital Expenditures Change (Q3 TTM) 0.16 % 6.42 % 0.99 % 23.05 %
Capital Expenditures 5 Year Avg. Change 22.72 % 9.64 % 8.61 % 14.19 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Y/Y Annual




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.